Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4.

Antiviral therapy - 1 Jan 2008

Lee Samuel S, Ferenci Peter

Abstract excerpt

Currently, many decisions for the treatment of hepatitis C virus (HCV) are based on genotype, which is the most significant baseline predictor of response to therapy; however, it has become increasingly apparent that fixed treatment durations might not be appropriate for all patients. The use of on-treatment predictors such as rapid virological response (RVR) at week 4 and early virological response (EVR) at week...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase III as Topic
Share to Drug Therapy, Combination
Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Randomized Controlled Trials as Topic

Share to Ribavirin

Source

Identifiers

PMID: 18432158

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4.PMID 18432158Read ↗

Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3.Semantic proximity Read ↗

Hepatitis C treatment: shorter and better?Semantic proximity Read ↗

Reducing treatment duration in patients infected with hepatitis C genotype 1: any need for further studies?Semantic proximity Read ↗

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.Semantic proximity Read ↗

Optimal therapy in genotype 1 patients.Semantic proximity Read ↗

Treatment of hepatitis C in 2011: what can we expect?Semantic proximity Read ↗

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.Semantic proximity Read ↗

Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.Semantic proximity Read ↗

Improving outcome in patients with hepatitis C virus genotype 4.Semantic proximity Read ↗

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.Semantic proximity Read ↗

Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.Semantic proximity Read ↗

Viral factors affecting the outcome of therapy for chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.